[go: up one dir, main page]

GB1140316A - Influenza virus sub-unit vaccine - Google Patents

Influenza virus sub-unit vaccine

Info

Publication number
GB1140316A
GB1140316A GB8458/67A GB845867A GB1140316A GB 1140316 A GB1140316 A GB 1140316A GB 8458/67 A GB8458/67 A GB 8458/67A GB 845867 A GB845867 A GB 845867A GB 1140316 A GB1140316 A GB 1140316A
Authority
GB
United Kingdom
Prior art keywords
concentration
vaccine
influenza virus
salt
feb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB8458/67A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Australian National University
Original Assignee
Australian National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Australian National University filed Critical Australian National University
Publication of GB1140316A publication Critical patent/GB1140316A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1,140,316. Influenza vaccine. AUSTRALIAN NATIONAL UNIVERSITY. 22 Feb., 1967 [24 Feb., 1966; 7 April, 1966], No. 8458/67. Heading A5B. Influenza vaccine is prepared by treating an aqueous suspension of influenza virus particles with an aqueous solution of a soluble salt of desoxycholic acid, whereby the particles are split into sub-units, and then reducing the concentration of the said salt in the vaccine to a non-toxic level. The preferred salt is sodium desoxycholate which is added to the suspension to give a concentration of 0.5 to 2.0% wt./vol., the concentration subsequently being reduced to below 0.01%, e.g. by dialysis. The treatment may be performed at 20‹-37‹C, at pH 7.5-8.2, and takes from 1 to 60 minutes. Virus strains used are swine (SW) strain 15 of shope, BEL strain, Asian AS(A<SP>2</SP>/AA/23/57), and two Australian strains, A<SP>2</SP>/SA/64 and B/Vic/65; they are grown up in embryonate egg culture prior to treatment.
GB8458/67A 1966-02-24 1967-02-22 Influenza virus sub-unit vaccine Expired GB1140316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2078/66A AU405949B1 (en) 1966-02-24 1966-02-24 Influenza virus sub-unit vaccine
AU396166 1966-04-07

Publications (1)

Publication Number Publication Date
GB1140316A true GB1140316A (en) 1969-01-15

Family

ID=25609454

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8458/67A Expired GB1140316A (en) 1966-02-24 1967-02-22 Influenza virus sub-unit vaccine

Country Status (5)

Country Link
AU (1) AU405949B1 (en)
DK (1) DK114644B (en)
FR (1) FR1587329A (en)
GB (1) GB1140316A (en)
NL (1) NL6702701A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
US10946088B2 (en) 2008-03-18 2021-03-16 Seqirus UK Limited Preparation of influenza virus vaccine antigens

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8502096D0 (en) * 1985-01-28 1985-02-27 Medical Res Council Influenza vaccine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
US10946088B2 (en) 2008-03-18 2021-03-16 Seqirus UK Limited Preparation of influenza virus vaccine antigens

Also Published As

Publication number Publication date
NL6702701A (en) 1967-08-25
FR1587329A (en) 1970-03-20
DK114644B (en) 1969-07-21
AU405949B1 (en) 1970-09-18
DE1617288A1 (en) 1971-02-18

Similar Documents

Publication Publication Date Title
Cohen et al. A nerve growth-stimulating factor isolated from sarcom as 37 and 180
Srere [88] Citrate-cleavage enzyme: Citrate+ ATP+ coenzyme A Mg++ Acetyl coenzymo A+ oxalacetate+ ADP+ Pi
Neitz Aureomycin in Thieileria parva Infection
GB1140316A (en) Influenza virus sub-unit vaccine
Walker A method for the isolation of toxic and immunizing fractions from bacteria of the Salmonella group
Gaunt et al. The life-maintaining effect of crystalline progesterone in adrenalectomized ferrets
GB697351A (en) Improved process for the manufacture of nerve sedatives
Russell et al. Mumps Viral Cytolysin: I. Action on Human Epithelial Cells in Tissue Culture
Yunker et al. Growth of Colorado tick fever (CTF) virus in primary tissue cultures of its vector, Dermacentor andersoni Stiles (Acarina: ixodidae), with notes on tick tissue culture
US2917435A (en) Preparation of 2-keto-1-gulonic acid by pseudomonas aeruginosa
Bailey α-Galactosidase activity of rumen bacteria
GB1436684A (en) Method for preparing glucoronyl-glucosamino-glycan sulphates exhibiting antilipaemic activity
GB660109A (en) Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
Beadle et al. Carbon dioxide narcosis
Cairns Multiplicity reactivation of influenza virus
Plotz et al. In vitro cultivation of the street virus of rabies
Cutts et al. Nutrition of a strain of brewer's yeast requiring p-aminobenzoic acid
US2445301A (en) Influenza vaccine
GB1026726A (en) New assay technique
GB953992A (en) Vaccine products and method of preparing same
Moss Sodium nucleate inhibition of arginase activity
Miller et al. Acetyl and phenylureido Derivatives of tobacco mosaic virus
Mack et al. Serological response in chickens to beta-propiolactone treated Newcastle disease virus
Nielsen et al. Activation of wheat germ acetyl CoA carboxylase by potassium and rubidium
Polley et al. THE USE OF BETA-PROPIOLACTONE FOR THE PREPARATION OF VIRUS VACCINES: I. SELECTION OF REACTION CONDITIONS